Slideshow

Vitamin D Status & Cardiovascular Disease Risk

Three studies examined the relationship between CVD risk and vitamin D status in children, adolescents, and women.

Studies presented at ENDO 2017 looked at the relationship between CVD risk and vitamin D status. Researchers examined the impact of vitamin D status and lipid markers on CV risk during childhood, and studied vitamin D status and CVD risk in two female populations.

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Related Content
Jörn M. Schattenberg, MD | Credit: LinkedIn
December 15th 2024

Study Highlights Real-World Mortality Rates, Factors Increasing Mortality Risk in MASH

Patrick Campbell
Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor
December 16th 2024

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia | Image Credit: US Food and Drug Administration
Published: December 13th 2024 | Updated: December 13th 2024

FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia

Connor Iapoce
Irl Hirsch, MD | Credit: University of Washington
December 12th 2024

Diabetes Dialogue: Celebrating 25 Years of CGM, with Irl Hirsch, MD

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
A Pillared Approach: A Suite of THerapies for a Spectrum of Metabolic Disease
December 6th 2024

A Pillared Approach: A Suite of Therapies for a Spectrum of Metabolic Disease

Patrick Campbell
Stock image of body weight scale. | Credit: iStock
December 4th 2024

SURMOUNT-5: Tirzepatide Bests Semaglutide in Head-to-Head Weight Loss Trial

Patrick Campbell
© 2024 MJH Life Sciences

All rights reserved.